4 results about "Orf2 gene" patented technology

The invention relates to the technical field of medicine, in particular to a porcine circovirus type 3 Cap recombinant protein and a matched detection method and application thereof.According to the porcine circovirus type 3 Cap recombinant protein, efficient and high-quality preparation is achieved through gene optimization and expression process improvement, Escherichia coli rare codons in ORF2 genes are replaced with GeneOptimizer software, an unfavorable structure rich in arginine at the N end is removed, and the recombinant protein is obtained. The mRNA stability and the translation efficiency are obviously improved; through IPTG induction condition optimization and'inclusion body treatment-Ni-NTA affinity chromatography-dialysis renaturation 'purification processes, the final protein purity exceeds 95%, a high-quality material basis is provided for subsequent detection, the matched indirect ELISA detection method has the core characteristics of'accuracy, high efficiency and stability', detection can be completed within 2-3 h, synchronous analysis of large-batch samples is supported, and the detection efficiency is greatly improved.

Virus-Like Particles derived from the subfamilies, Parahepevirinae, which infect trout and salmon, and the Orthohepevirinae, which infect mammals and birds, particularly those of the species Paslahepevirus balayani, which can cause acute hepatitis in humans and several mammalian species, and chronic conditions in immunocompromised patients are also disclosed. Major aspects of the invention relate to compositions of Virus-Like Particles comprising viral capsid proteins capable of assembly in cultured cells that may be purified, disassembled, and reassembled in the presence of other molecules suitable for use as therapeutic drug products to facilitate the targeting and delivery of cargo molecules to specific cells or tissues, or as antigenic agents designed to stimulate responses to heterologous epitopes exposed on the surfaces of Virus-Like Particles. Preferred aspects relate to functional capsids comprising polypeptide sequences comprising one or more amino acid substitutions, insertions, or deletions of amino acid encoded by a consensus of ORF2 genes, wherein said variant polypeptides are functionally-similar or have enhanced properties compared to capsid polypeptides encoded by naturally-occurring viruses obtained from clinical samples or prototype Hepatitis E Viruses (HEV). Other aspects include the design and assembly of modified vectors to facilitate the basic and applied studies leading to the development and commercialization of novel drug products, and as tools advancing the interests of institutions involved in animal and human healthcare.

Virus-Like Particles derived from the subfamilies, Parahepevirinae and Orthohepevirinae, particularly those of the species Paslahepevirus balayani, which can cause acute hepatitis in humans and several mammalian species, and chronic conditions in immunocompromised patients are disclosed. Compositions of VirusLike Particles comprising viral capsid proteins capable of assembly in cultured cells that may be purified, disassembled, and reassembled in the presence of other molecules suitable for use as therapeutic drug products to facilitate the targeting and delivery of cargo molecules to specific cells or tissues, or as antigenic agents designed to stimulate responses to heterologous epitopes exposed on the surfaces of Virus- Like Particles are provided. Functional capsids comprising polypeptide sequences comprising amino acid substitutions, insertions, or deletions of amino acid encoded by a consensus of ORF2 genes, that are functionally-similar or have enhanced properties compared to capsid polypeptides encoded by naturally-occurring viruses obtained from clinical samples or prototype Hepatitis E Viruses (HEV) are provided.

The invention provides a preparation method of a triple recombinant vaccine, which is mainly used for preparing rabbit hemorrhagic syndrome, rabbit hepatitis E and rabbit pox virus recombinant vaccines. The method comprises the following steps: extracting RHDV VP60 and HEV-ORF2 genes, constructing recombinant plasmids, transfecting the recombinant plasmids into competent cells, screening and identifying the recombinant plasmids, culturing the recombinant plasmids in rabbit kidney cells, amplifying after pressurizing and screening, harvesting recombinant viruses, repeatedly freezing and thawing, and freezing and storing. The purpose of preventing rabbit pox viruses, rabbit hepatitis E and rabbit viral syndromes is achieved by vaccination of rabbits, production is easy, the problem of cold storage does not exist, three viruses are prevented through one injection, meat body pain and local red and swollen caused by multiple injections to animals are avoided, and stress response is reduced. Meanwhile, the rabbit pox is a carrier of the species, so that the interference caused by a non-species carrier is reduced, the stimulation to inoculated animals is small, the immune effect is strong and the like, and the research of the rabbit pox carrier vaccine has wide theoretical significance and practical significance.